The PD-(L)1 Patent Cliff: Implications for Oncology Pricing
A strategic guide for navigating the biosimilar transition
Between 2028 and 2035 patent protection for major PD-(L)1 checkpoint inhibitors will expire across key markets. Keytruda, Opdivo, Tecentriq and Imfinzi, the economic anchors of modern cancer care, will face biosimilar competition that will fundamentally reshape oncology pricing and market access strategies. This isn't just another Loss of Exclusivity (LOE) cycle. With biosimilars already in clinical trials and subcutaneous formulations creating new competitive dynamics, pricing and market access leaders need strategic guidance now to navigate the most significant transition in oncology market access in recent history.
Our latest resource delivers actionable intelligence on pricing erosion, competitive positioning and stakeholder strategies across key markets to help you prepare for the biosimilar wave from 2028 and beyond.
Why download?
Market Intelligence: Understand regional pricing erosion patterns of nearly 40% across key regions including US, Europe and Japan.
Competitive Positioning: Evaluate how subcutaneous formulations from Merck, BMS and Roche are extending lifecycle value ahead of IV biosimilar entry.
Portfolio Strategy: Discover how falling PD-(L)1 costs resets combination therapy economics, creating both budget headroom for payers and new benchmarks for innovative add-ons.
Strategic Playbooks: Access tailored guidance for originator manufactures, biosimilar developers and combination innovators navigating the 2028-2033 transition.
What's inside?
Patent expiry timeline with LOE dates across US, EU and Japan.
Regional pricing erosion forecast and competitive tender dynamics.
Opportunity areas for originators, biosimilar developers and combination therapy innovators.
Priority actions for market access leaders to prepare for the biosimilar shift.
This Resource is Essential For: Oncology market access directors, pricing strategists and HEOR leaders preparing for the PD-(L)1 biosimilar shift. Ideal for teams managing global launches, reimbursement strategy, lifecycle planning and portfolio optimisation across originators, biosimilars and emerging combination therapies.
Get Your Resource
Wondering how the PD-(L)1 biosimilar transition will affect your pricing or launch strategy?
Our oncology pricing specialists can help you stress-test scenarios, evaluate regional erosion risks and define the right access strategy for your portfolio.
We offer tailored guidance grounded in real-world pricing data, biosimilar uptake patterns and market-specific dynamics, so you can prepare with confidence.